The Governors of the University of Calgary

Brain Cancer Canada has awarded $68,000 to researchers at the University of Calgary and Alberta Children's Hospital for a clinical trial of a neoantigen-based anti-cancer vaccine targeting DIPG, the most aggressive form of pediatric brain cancer.

Two major clinical trials demonstrate that hybrid closed-loop insulin delivery systems significantly improve time in range and reduce hypoglycemia in pregnant women with type 1 diabetes compared to standard care.

The FDA has approved Genentech's TNKase, a clot-dissolving agent, for treating acute ischemic stroke in adults, marking the company's second stroke treatment approval.

A large Canadian retrospective study of 32,667 preterm infants reveals probiotics significantly reduced mortality rates, with an adjusted odds ratio of 0.62 in infants born before 34 weeks gestation.

Late-breaking ESCAPE-MeVO trial results reveal endovascular thrombectomy combined with best medical care offers no additional benefit over best medical care alone for medium-vessel occlusion stroke patients.

• University of Calgary researchers are initiating a validation study for the Mira Hormone Monitor, a device claiming to provide precise numerical readings of hormone biomarkers from urine samples. • The study, requiring Health Canada clearance, aims to validate the device's claimed 99% lab-grade accuracy using ultrasound testing as the gold standard for comparison. • The technology could revolutionize women's healthcare by enabling daily hormone tracking for conditions like PCOS and PMS, while providing comprehensive data for healthcare providers.

A clinical trial at the University of Calgary is testing probenecid, a gout medication, to alleviate opioid withdrawal symptoms.

A clinical trial found that ustekinumab, a drug currently used for psoriasis, preserved insulin production in young type 1 diabetes patients, with C-peptide levels 49% higher after one year compared to placebo.

Elranatamab demonstrated a 61% objective response rate in patients with penta- or triple-class refractory multiple myeloma who had not received prior BCMA-targeted therapy.